Symbols / NNVC
NNVC Chart
About
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 22.43M |
| Enterprise Value | 17.31M | Income | -8.32M | Sales | — |
| Book/sh | 0.51 | Cash/sh | 0.24 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -2.97 | PEG | — |
| P/S | — | P/B | 2.03 | P/C | — |
| EV/EBITDA | -2.23 | EV/Sales | — | Quick Ratio | 4.31 |
| Current Ratio | 4.43 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.50 | EPS next Y | -0.35 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-17 16:00 | ROA | -44.02% |
| ROE | -77.53% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 21.57M |
| Shs Float | 19.63M | Short Float | 3.77% | Short Ratio | 2.64 |
| Short Interest | — | 52W High | 2.23 | 52W Low | 0.85 |
| Beta | 1.32 | Avg Volume | 306.76K | Volume | 89.34K |
| Target Price | $6.50 | Recom | None | Prev Close | $1.01 |
| Price | $1.04 | Change | 2.97% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.50
Mean price target
2. Current target
$1.04
Latest analyst target
3. DCF / Fair value
$-3.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.04
Low
$6.00
High
$7.00
Mean
$6.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-05-07 | reit | EF Hutton | Buy → Buy | $7 |
| 2024-02-16 | reit | EF Hutton | Buy → Buy | $7 |
| 2023-04-18 | reit | EF Hutton | — → Buy | $5 |
- Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan ue, 10 Feb 2026 08
- NanoViricides: Fiscal Q2 Earnings Snapshot - WWLTV.com ue, 17 Feb 2026 21
- 2 Small-Cap Biotechs That Could Reward Patient Investors - Yahoo Finance Fri, 12 Dec 2025 08
- NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study - Proactive financial news hu, 19 Feb 2026 08
- Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us hu, 03 Dec 2020 11
- Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? - Yahoo Finance Fri, 14 Feb 2025 08
- NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split - BioSpace hu, 12 Sep 2019 07
- NanoViricides' Game-Changing Antiviral Shows Superior Results Against Multiple Viruses - Stock Titan ue, 11 Mar 2025 07
- NNVC Stock Price and Chart — AMEX:NNVC - TradingView Fri, 21 Jul 2017 02
- 3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire - Nasdaq hu, 02 May 2024 07
- Cashing in on coronavirus: Small biopharma company NanoViricides sees stock soar on treatment claims - CNBC ue, 14 Jul 2020 07
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - ACCESS Newswire hu, 12 Feb 2026 13
- NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Yahoo Finance Mon, 14 Oct 2024 07
- NanoViricides raises $6M in direct offering with institutional investor - Proactive financial news ue, 11 Nov 2025 08
- NanoViricides to present antiviral drug pipeline at Biotech Showcase 2025 | NYSE-A:NNVC - Proactive financial news Mon, 13 Jan 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -8.72M | -7.49M | -7.84M | -7.38M |
| TotalUnusualItems | 0.00 | -2.03K | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | -2.03K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.47M | -8.29M | -8.59M | -8.11M |
| ReconciledDepreciation | 743.80K | 759.01K | 747.53K | 723.33K |
| EBITDA | -8.72M | -7.49M | -7.84M | -7.38M |
| EBIT | -9.47M | -8.24M | -8.59M | -8.10M |
| NetInterestIncome | 124.68K | 221.97K | 354.89K | 6.74K |
| InterestExpense | 149.00 | 49.81K | 938.00 | 5.12K |
| InterestIncome | 124.83K | 271.77K | 355.83K | 11.86K |
| NormalizedIncome | -9.47M | -8.29M | -8.59M | -8.11M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.47M | -8.29M | -8.59M | -8.11M |
| TotalExpenses | 9.59M | 8.52M | 8.94M | 8.11M |
| TotalOperatingIncomeAsReported | -9.59M | -8.52M | -8.94M | -8.11M |
| DilutedAverageShares | 15.12M | 11.87M | 11.63M | 11.53M |
| BasicAverageShares | 15.12M | 11.87M | 11.63M | 11.53M |
| DilutedEPS | -0.63 | -0.70 | -0.74 | -0.70 |
| BasicEPS | -0.63 | -0.70 | -0.74 | -0.70 |
| DilutedNIAvailtoComStockholders | -9.47M | -8.29M | -8.59M | -8.11M |
| NetIncomeCommonStockholders | -9.47M | -8.29M | -8.59M | -8.11M |
| NetIncome | -9.47M | -8.29M | -8.59M | -8.11M |
| NetIncomeIncludingNoncontrollingInterests | -9.47M | -8.29M | -8.59M | -8.11M |
| NetIncomeContinuousOperations | -9.47M | -8.29M | -8.59M | -8.11M |
| TaxProvision | 0.00 | 0.00 | ||
| PretaxIncome | -9.47M | -8.29M | -8.59M | -8.11M |
| OtherIncomeExpense | -2.03K | |||
| SpecialIncomeCharges | 0.00 | -2.03K | ||
| GainOnSaleOfPPE | 0.00 | -2.03K | ||
| NetNonOperatingInterestIncomeExpense | 124.68K | 221.97K | 354.89K | 6.74K |
| InterestExpenseNonOperating | 149.00 | 49.81K | 938.00 | 5.12K |
| InterestIncomeNonOperating | 124.83K | 271.77K | 355.83K | 11.86K |
| OperatingIncome | -9.59M | -8.52M | -8.94M | -8.11M |
| OperatingExpense | 9.59M | 8.52M | 8.94M | 8.11M |
| ResearchAndDevelopment | 5.55M | 5.44M | 6.39M | 5.78M |
| SellingGeneralAndAdministration | 4.04M | 3.08M | 2.55M | 2.33M |
| GeneralAndAdministrativeExpense | 4.04M | 3.08M | 2.55M | 2.33M |
| OtherGandA | 4.04M | 3.08M | 2.55M | 2.33M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-06-30 | |||
|---|---|---|---|---|
| PreferredSharesNumber | 903.22K | |||
| OrdinarySharesNumber | 16.61M | 13.14M | 11.70M | 11.59M |
| ShareIssued | 16.61M | 13.14M | 11.70M | 11.59M |
| TotalDebt | 94.79K | 95.31K | ||
| TangibleBookValue | 7.20M | 11.14M | 14.53M | 22.74M |
| InvestedCapital | 7.52M | 11.46M | 14.87M | 23.18M |
| WorkingCapital | 364.19K | 3.61M | 7.91M | 14.00M |
| NetTangibleAssets | 7.20M | 11.14M | 14.53M | 22.74M |
| CommonStockEquity | 7.52M | 11.46M | 14.87M | 23.08M |
| PreferredStockEquity | 9.00 | 9.00 | 5.00 | 5.00 |
| TotalCapitalization | 7.52M | 11.46M | 14.87M | 23.08M |
| TotalEquityGrossMinorityInterest | 7.52M | 11.46M | 14.87M | 23.08M |
| StockholdersEquity | 7.52M | 11.46M | 14.87M | 23.08M |
| RetainedEarnings | -148.84M | -139.37M | -131.08M | -122.49M |
| AdditionalPaidInCapital | 156.36M | 150.84M | 145.95M | 145.57M |
| CapitalStock | 175.00 | 140.00 | 122.00 | 121.00 |
| CommonStock | 166.00 | 131.00 | 117.00 | 116.00 |
| PreferredStock | 9.00 | 9.00 | 5.00 | 5.00 |
| TotalLiabilitiesNetMinorityInterest | 1.31M | 1.36M | 2.03M | 412.84K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 1.50M | 0.00 |
| OtherNonCurrentLiabilities | 1.50M | |||
| DuetoRelatedPartiesNonCurrent | 0.00 | 1.50M | ||
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | ||
| CurrentLiabilities | 1.31M | 1.36M | 534.25K | 412.84K |
| CurrentDebtAndCapitalLeaseObligation | 94.79K | 95.31K | ||
| CurrentDebt | 94.79K | 95.31K | ||
| OtherCurrentBorrowings | 95.31K | |||
| LineOfCredit | 0.00 | 94.79K | 95.31K | |
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 25.97K | 23.53K | 39.06K | 38.68K |
| PayablesAndAccruedExpenses | 1.28M | 1.34M | 495.19K | 279.37K |
| CurrentAccruedExpenses | 0.00 | 238.94K | 104.70K | 7.02K |
| Payables | 1.28M | 1.10M | 390.49K | 272.36K |
| DuetoRelatedPartiesCurrent | 720.04K | 233.43K | 214.40K | 31.54K |
| AccountsPayable | 1.28M | 1.10M | 390.49K | 57.96K |
| TotalAssets | 8.82M | 12.82M | 16.90M | 23.49M |
| TotalNonCurrentAssets | 7.15M | 7.85M | 8.45M | 9.08M |
| OtherNonCurrentAssets | 2.44K | 14.56K | 14.36K | 38.92K |
| NonCurrentPrepaidAssets | 0.00 | 3.52K | 3.52K | |
| NonCurrentDeferredAssets | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 317.04K | 325.31K | 333.58K | 341.85K |
| OtherIntangibleAssets | 317.04K | 325.31K | 333.58K | 341.85K |
| NetPPE | 6.83M | 7.51M | 8.11M | 8.69M |
| AccumulatedDepreciation | -8.19M | -7.45M | -6.70M | -5.96M |
| GrossPPE | 15.02M | 14.97M | 14.81M | 14.66M |
| OtherProperties | 6.51M | 6.47M | 6.32M | 6.19M |
| MachineryFurnitureEquipment | 8.25M | 8.24M | 8.23M | 8.21M |
| LandAndImprovements | 260.00K | 260.00K | 260.00K | 260.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.67M | 4.97M | 8.45M | 14.42M |
| PrepaidAssets | 112.15K | 172.74K | 295.49K | 350.02K |
| CashCashEquivalentsAndShortTermInvestments | 1.56M | 4.80M | 8.15M | 14.07M |
| CashAndCashEquivalents | 1.56M | 4.80M | 8.15M | 14.07M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -8.54M | -6.47M | -5.82M | -6.22M |
| RepaymentOfDebt | 0.00 | -94.79K | -234.72K | -1.30M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 5.30M | 3.12M | 0.00 | 0.00 |
| CapitalExpenditure | -56.96K | -156.56K | -151.71K | -324.35K |
| InterestPaidSupplementalData | 149.00 | 0.00 | 938.00 | 5.12K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | |
| EndCashPosition | 1.56M | 4.80M | 8.15M | 14.07M |
| BeginningCashPosition | 4.80M | 8.15M | 14.07M | 20.52M |
| ChangesInCash | -3.24M | -3.35M | -5.92M | -6.45M |
| FinancingCashFlow | 5.30M | 3.12M | -94.79K | -234.72K |
| CashFlowFromContinuingFinancingActivities | 5.30M | 3.12M | -94.79K | -234.72K |
| NetCommonStockIssuance | 5.30M | 3.12M | 0.00 | 0.00 |
| CommonStockIssuance | 5.30M | 3.12M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | -94.79K | -234.72K | -1.30M |
| NetShortTermDebtIssuance | -94.79K | -234.72K | -203.01K | |
| ShortTermDebtPayments | -94.79K | -234.72K | -203.01K | |
| NetLongTermDebtIssuance | 0.00 | -94.79K | 0.00 | -1.10M |
| LongTermDebtPayments | 0.00 | -94.79K | 0.00 | -1.10M |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -56.96K | -156.56K | -151.71K | -324.35K |
| CashFlowFromContinuingInvestingActivities | -56.96K | -156.56K | -151.71K | -324.35K |
| NetPPEPurchaseAndSale | -56.96K | -156.56K | -151.71K | -324.35K |
| PurchaseOfPPE | -56.96K | -156.56K | -151.71K | -324.35K |
| OperatingCashFlow | -8.48M | -6.32M | -5.67M | -5.89M |
| CashFlowFromContinuingOperatingActivities | -8.48M | -6.32M | -5.67M | -5.89M |
| ChangeInWorkingCapital | 20.46K | 996.88K | 1.80M | 214.56K |
| ChangeInOtherCurrentLiabilities | 0.00 | 1.50M | 0.00 | |
| ChangeInOtherCurrentAssets | 12.12K | -201.00 | 28.08K | -38.92K |
| ChangeInPayablesAndAccruedExpense | -52.26K | 874.33K | 216.20K | 62.21K |
| ChangeInAccruedExpense | -236.50K | 168.52K | 98.07K | 21.41K |
| ChangeInPayable | 184.24K | 705.82K | 118.13K | 40.80K |
| ChangeInAccountPayable | 184.24K | 705.82K | 118.13K | 40.80K |
| ChangeInPrepaidAssets | 60.60K | 122.74K | 54.53K | 191.28K |
| OtherNonCashItems | 156.99K | 935.09K | 30.20K | |
| StockBasedCompensation | 223.35K | 222.19K | 214.18K | 338.42K |
| DepreciationAmortizationDepletion | 743.80K | 759.01K | 747.53K | 723.33K |
| DepreciationAndAmortization | 743.80K | 759.01K | 747.53K | 723.33K |
| AmortizationCashFlow | 8.27K | 8.27K | 8.27K | 8.27K |
| AmortizationOfIntangibles | 8.27K | 8.27K | 8.27K | 8.27K |
| Depreciation | 735.54K | 750.74K | 739.26K | 715.05K |
| OperatingGainsLosses | 679.00 | 563.00 | 1.01K | 4.21K |
| GainLossOnInvestmentSecurities | 679.00 | 563.00 | 1.01K | 4.21K |
| GainLossOnSaleOfPPE | 0.00 | 2.03K | ||
| NetIncomeFromContinuingOperations | -9.47M | -8.29M | -8.59M | -8.11M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NNVC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|